QQ客服 官方微博 反馈留言

	The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)
	Liu, Liang; Xiang, Jinfeng; Chen, Rufu; Fu, Deliang; Hong, Defei; Hao, Jihui; Li, Yixiong; Li, Jiangtao; Li, Shengping; Mou, Yiping
刊名	INTERNATIONAL JOURNAL OF ONCOLOGY
	2016
卷号	48期号:3
关键词	pancreatic cancer cancer antigen 125 mucin 16 diagnosis predictive potency prognosis
ISSN号	1019-6439
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4287853
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Liu, Liang,Xiang, Jinfeng,Chen, Rufu,et al. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)[J]. INTERNATIONAL JOURNAL OF ONCOLOGY,2016,48(3).
APA	Liu, Liang.,Xiang, Jinfeng.,Chen, Rufu.,Fu, Deliang.,Hong, Defei.,...&Yu, Xianjun.(2016).The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC).INTERNATIONAL JOURNAL OF ONCOLOGY,48(3).
MLA	Liu, Liang,et al."The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)".INTERNATIONAL JOURNAL OF ONCOLOGY 48.3(2016).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。